Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul;30(4):951-7.
doi: 10.1111/jvim.13951. Epub 2016 May 6.

Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs

S S Tjostheim  1 , R L Stepien  1 , L E Markovic  1 , T J Stein  1
Affiliations

Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs

S S Tjostheim et al. J Vet Intern Med. 2016 Jul.

Abstract

Background: Systemic hypertension and proteinuria are established adverse effects of tyrosine kinase inhibitor treatment in people.

Objective: The objective of this study was to investigate changes in systolic blood pressure and the incidence of proteinuria secondary to treatment with toceranib phosphate in dogs with cancer.

Animals: Twenty-six control dogs and 30 dogs with cancer were evaluated for the first part of the study (baseline characteristics). For the second part (effect of toceranib phosphate treatment), 48 client-owned dogs were evaluated, including 20 control dogs and 28 dogs with various types of neoplasia.

Methods: Prospective cohort study. Client-owned healthy control dogs and dogs with cancer were enrolled. Blood pressure and urine protein:creatinine ratios were measured before treatment and 2 weeks after initiation of toceranib phosphate treatment.

Results: Systolic blood pressure was significantly (P = 0.0013) higher in previously normotensive treatment dogs after initiation of treatment with toceranib phosphate (152 mmHg ± 19) compared to baseline (136 mmHg ± 14). 37% of treated dogs developed SBP ≥ 160 mmHg. The prevalence of systemic hypertension (37%) and proteinuria (21%) at baseline in treatment dogs did not differ from that of age-matched healthy controls (15% [P = 0.13] and 0% [P = 0.069], respectively).

Conclusions and clinical importance: Toceranib phosphate treatment might result in increased systolic blood pressures in dogs. Systemic hypertension should be considered a potential adverse effect of this drug in dogs. Systemic hypertension and proteinuria were detected at clinically relevant frequencies in the dogs with cancer before antineoplastic therapies suggesting that monitoring of these variables might be warranted in this population.

Keywords: Angiogenesis inhibitors; Chemotherapy; Systemic hypertension; Tyrosine kinase inhibitors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean (SD) systolic blood pressure (SBP, mmHg) at visit 1 (BP1) and visit 2 (BP2) in all groups. Significant differences are indicated with P values.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:101–1027. - PubMed
    1. London C, Mathie T, Stingle N, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours. Vet Comp Oncol 2012;10:194–205. - PMC - PubMed
    1. Kruzliak P, Novak J, Novak M. Vascular endothelial growth factor inhibition‐induced hypertension: From pathophysiology to prevention and treatment based on long‐acting nitric oxide donors. Am J Hypertens 2014;27:3–12. - PubMed
    1. Bhargava P. VEGF kinase inhibitors: How do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 2009;297:R1–R5. - PubMed
    1. Azizi M, Chedid A, Oudard S. Home blood‐pressure monitoring in patients receiving sunitinib. N Engl J Med 2008;358:95–97. - PubMed

MeSH terms